Skip to main content

Big Pharma Buys Into Tranzyme

Big pharma is putting its money on Tranzyme Pharma.

Tranzyme, a 7-year-old Research Triangle Park-based clinical-stage pharmaceutical company, started with the help of a $150,000 Biotechnology Center loan in 2003.

The firm has received more than $250 million in partnership agreements in recent months from drug giants Bristol-Myers Squibb and Europe's Norgine B.V.

Vipin Garg, CEO, said the most recent agreement, with Norgine, helps move Tranzyme ahead in Europe with its target of developing drugs for unmet medical needs. The deal, worth as much as $158 million, is for developing a treatment for a muscle disorder in the gastrointestinal tract -- gastrointestinal dysmotility.

The Bristol deal, reached in December, put the privately held Tranzyme into a development partnership for additional gastrointestinal drugs in its pipeline.

Read the full news release